Physician profile
Alison Spellman
NPI 1629393970
$8,925.88
in general payments reported to CMS, 2019-2025
65 companies · $1,656 in 2025
The $1,656 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,143 · 2020: $283 · 2021: $640 · 2022: $1,172 · 2023: $1,515 · 2024: $1,517 · 2025: $1,656.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,688.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,688.48 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $831.64 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Novartis Pharmaceuticals Corporation | $774.99 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $514.64 | 2019-2025 | Opdivo, Opdualag |
| Amgen INC. | $472.27 | 2019-2023 | Kyprolis, Blincyto, Xgeva |
| Pfizer INC. | $377.82 | 2019-2025 | |
| Astrazeneca Pharmaceuticals Lp | $365.43 | 2019-2025 | Lynparza, Imfinzi, Calquence |
| Genentech USA, INC. | $301.41 | 2019-2025 | Itovebi, Polivy, Avastin |
| Astellas Pharma US INC | $285.97 | 2019-2025 | Xtandi, Padcev |
| Regeneron Healthcare Solutions, INC. | $281.93 | 2019-2025 | Libtayo, Lynozyfic |
| Daiichi Sankyo INC. | $270.32 | 2019-2025 | Enhertu, Injectafer |
| Incyte Corporation | $258.46 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Takeda Pharmaceuticals U.S.A., INC. | $229.23 | 2019-2025 | Iclusig, Ninlaro, Fruzaqla |
| Janssen Biotech, INC. | $227.21 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Gilead Sciences, INC. | $227.14 | 2021-2025 | Trodelvy |
| Celgene Corporation | $205.08 | 2019-2023 | Reblozyl, Pomalyst |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Eisai INC. | $202.67 | 2019-2024 | |
| Genzyme Corporation | $186.22 | 2019-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $176.92 | 2019-2024 | |
| Adaptive Biotechnologies Corporation | $172.23 | 2021-2023 | Clonoseq |
| Ipsen Biopharmaceuticals, INC | $158.30 | 2019-2025 | Onivyde, Somatuline Depot |
| Lilly USA, LLC | $151.07 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Acrotech Biopharma INC. | $145.90 | 2022-2025 | Beleodaq |
| Seagen INC. | $131.61 | 2019-2023 | Padcev, Adcetris |
| Puma Biotechnology, INC. | $124.80 | 2021-2024 | |
| Exelixis INC. | $122.39 | 2019-2024 | Cabometyx |
| Pharmacyclics LLC, An Abbvie Company | $113.19 | 2019-2023 | Imbruvica |
| Array Biopharma INC | $113.00 | 2019-2025 | Braftovi, Lorbrena, Mektovi |
| Glaxosmithkline, LLC. | $105.62 | 2021-2025 | Ojjaara, Blenrep, Jemperli |
| Secura Bio, INC. | $102.56 | 2023 | Copiktra |
| Kite Pharma, INC. | $97.96 | 2023-2025 | Yescarta |
| Octapharma USA, INC. | $96.56 | 2022-2024 | Octagam Immune Globulin (Human) |
| Spr Therapeutics, INC | $93.93 | 2025 | Sprint Pns System |
| Abbvie INC. | $87.25 | 2023-2025 | Venclexta |
| Stemline Therapeutics INC. | $73.76 | 2024-2025 | Orserdu |
| Alexion Pharmaceuticals, INC. | $61.99 | 2021-2024 | Ultomiris |
| G1 Therapeutics, INC. | $58.99 | 2022-2023 | Cosela |
| Emd Serono, INC. | $54.65 | 2019-2020 | |
| Taiho Oncology, INC. | $53.34 | 2019-2025 | |
| Karyopharm Therapeutics INC. | $52.03 | 2021-2023 | Xpovio |
| Beone Medicines USA, INC. | $44.01 | 2025 | Brukinsa |
| Pharmacosmos Therapeutics INC. | $43.17 | 2022-2024 | Cosela |
| Adc Therapeutics America, INC. | $34.21 | 2024 | |
| Rigel Pharmaceuticals, INC. | $32.84 | 2025 | Gavreto, Tavalisse, Rezlidhia |
| Heron Therapeutics, INC. | $31.90 | 2019 | |
| Recordati_rare_diseases_inc. | $31.21 | 2025 | Sylvant |
| Beigene USA, INC. | $31.01 | 2023-2025 | Brukinsa |
| Apellis Pharmaceuticals, INC. | $25.14 | 2025 | Empaveli |
| Genmab U.S., INC. | $20.37 | 2024 | Epkinly |
| Servier Pharmaceuticals LLC | $20.21 | 2024 | |
| Deciphera Pharmaceuticals INC. | $20.06 | 2024 | Qinlock, Tgct |
| Tesaro, INC. | $18.36 | 2019 | |
| Shire North American Group INC | $17.96 | 2019 | |
| Agios Pharmaceuticals, INC. | $17.90 | 2023 | Pyrukynd |
| Springworks Therapeutics, INC. | $17.79 | 2025 | Ogsiveo |
| Mylan Institutional INC. | $16.84 | 2022 | |
| Sobi, INC | $16.77 | 2025 | |
| Cti Biopharma Corp. | $16.20 | 2023 | Vonjo |
| Kyowa Kirin, INC. | $16.17 | 2019 | |
| Aveo Pharmaceuticals, INC. | $15.94 | 2023 | Fotivda |
| Tersera Therapeutics LLC | $14.65 | 2022 | |
| Vifor Pharma, INC. | $13.80 | 2019 | |
| Janssen Pharmaceuticals, INC | $12.64 | 2021 | |
| Amag Pharmaceuticals, INC. | $12.49 | 2020 | |
| Lexicon Pharmaceuticals, INC. | $11.89 | 2020 | |
| Novocure INC. | $11.87 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Alison Spellman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.